Lantheus Holdings Inc (NASDAQ:LNTH) CFO John W. Crowley sold 3,866 shares of Lantheus stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $23.52, for a total transaction of $90,928.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Lantheus Holdings Inc (NASDAQ:LNTH) opened at $22.80 on Friday. Lantheus Holdings Inc has a fifty-two week low of $7.95 and a fifty-two week high of $24.10. The company has a debt-to-equity ratio of -3.41, a current ratio of 2.96 and a quick ratio of 2.46. The firm has a market cap of $862.70 and a price-to-earnings ratio of 28.50.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, November 2nd. The medical equipment provider reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.04. The business had revenue of $79.94 million during the quarter, compared to analysts’ expectations of $77.18 million. Lantheus had a net margin of 9.59% and a negative return on equity of 46.45%. The company’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.15 earnings per share. equities research analysts expect that Lantheus Holdings Inc will post 1.05 EPS for the current fiscal year.

A number of research analysts have weighed in on the stock. Zacks Investment Research cut shares of Lantheus from a “buy” rating to a “hold” rating in a report on Wednesday. ValuEngine cut shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, December 1st. BidaskClub raised shares of Lantheus from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Jefferies Group lifted their price objective on shares of Lantheus from $22.00 to $27.00 and gave the company a “buy” rating in a report on Friday, November 3rd. Finally, Wells Fargo & Co raised shares of Lantheus from a “market perform” rating to an “outperform” rating in a report on Thursday, November 2nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $24.25.

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Lantheus by 87.5% during the second quarter. Vanguard Group Inc. now owns 1,478,350 shares of the medical equipment provider’s stock worth $26,093,000 after purchasing an additional 689,954 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Lantheus by 73.7% during the third quarter. Dimensional Fund Advisors LP now owns 911,311 shares of the medical equipment provider’s stock worth $16,221,000 after purchasing an additional 386,771 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Lantheus by 12.6% during the second quarter. Renaissance Technologies LLC now owns 691,000 shares of the medical equipment provider’s stock worth $12,196,000 after purchasing an additional 77,200 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Lantheus by 60.7% during the third quarter. JPMorgan Chase & Co. now owns 690,419 shares of the medical equipment provider’s stock worth $12,220,000 after purchasing an additional 260,901 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Lantheus by 3,932.8% during the second quarter. State Street Corp now owns 617,014 shares of the medical equipment provider’s stock worth $10,891,000 after purchasing an additional 601,714 shares in the last quarter. 91.91% of the stock is owned by institutional investors and hedge funds.

WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.watchlistnews.com/insider-selling-lantheus-holdings-inc-lnth-cfo-sells-3866-shares-of-stock/1815553.html.

Lantheus Company Profile

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Insider Buying and Selling by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.